MedTrace Logo

Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery

NCT04058665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-04-14

No results posted yet for this study

Summary

Perioperative variables that can be used to create a bundled approach quality improvement protocol to minimize blood loss in spine surgery will be evaluated using retrospective data collection and multivariate analysis of previously performed spinal surgeries at Johns Hopkins Hospital. In particular the investigators are interested in determining whether FloSeal® contributes towards increased control over perioperative bleeding compared to other hemostatic agents for potential inclusion in a future bundled approach.

Conditions

  • Blood Loss

Interventions

DEVICE

Floseal

Hemostatic agent

Sponsors & Collaborators

Principal Investigators

  • Daniel M Sciubba, MD · Johns Hopkins University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-18
Primary Completion
2022-03-01
Completion
2022-03-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04058665 on ClinicalTrials.gov